The Technical Analyst
Enanta Pharmaceuticals [ENTA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Enanta Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.56% $12.55
America/New_York / 26 apr 2024 @ 13:16
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 265.51 mill |
| EPS: | -6.57 |
| P/E: | -1.910 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 21.16 mill |
| Avg Daily Volume: | 0.229 mill |
| RATING 2024-04-26 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.910 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.32x |
| Company: PE -1.910 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-8.35 (-166.54%) $-20.90 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 11.62 - 13.48 ( +/- 7.38%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-06 | Vance Terry | Buy | 15 700 | Stock Option (right to buy) |
| 2024-03-06 | Russell Lesley | Buy | 15 700 | Stock Option (right to buy) |
| 2024-03-06 | Peterson Kristine | Buy | 15 700 | Stock Option (right to buy) |
| 2024-03-06 | Hata Yujiro S | Buy | 15 700 | Stock Option (right to buy) |
| 2024-03-06 | Foletta Mark G | Buy | 15 700 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 70.19 |
| Last 100 transactions |
| Buy: 1 263 491 | Sell: 308 316 |
Forecast:
14:56 - $12.45
Live Trading Signals (every 1 min)
Forecast
1: 13:26 - $12.57
Forecast 2: 14:16 - $12.45
Forecast 3: 14:56 - $12.45
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $12.55 (0.56% ) |
| Volume | 0.0350 mill |
| Avg. Vol. | 0.229 mill |
| % of Avg. Vol | 15.27 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ENTA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $12.34 | N/A | Active |
|---|
ENTA
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Latest Press Releases
2024-04-17 07:00:00 - Press Release
Enanta Pharmaceuticals Announces Data Presentation At Escmid Global 2024
Watertown, mass.--(business wire)--enanta pharmaceuticals, inc. (nasdaq:enta), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that data from the company's sprint (sars-cov-2 protease inhibitor treatment) study of edp-235 has been accepted for a poster presentation at escmid global 2024 (formerly eccmid) being held april 27–30 in barcelona, spain. the poster presentation includes primary and post-hoc a.
2024-03-06 07:00:00 - Press Release
Enanta Pharmaceuticals To Participate At Leerink Partners Global Biopharma Conference
Watertown, mass.--(business wire)--enanta pharmaceuticals, inc. (nasdaq: enta), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that jay r. luly, ph.d., president and chief executive officer, and tara l. kieffer, ph.d., chief product strategy officer, will participate in a fireside chat at leerink partners global biopharma conference on march 13, 2024 at 10:40 a.m. et in miami, fl. a live webcast of th.
2024-02-07 16:01:00 - Press Release
Enanta Pharmaceuticals Reports Financial Results For Its Fiscal First Quarter Ended December 31, 2023 With Webcast And Conference Call Today At 4:30 P.m. Et
Watertown, mass.--(business wire)--enanta pharmaceuticals, inc. (nasdaq:enta), a clinical-stage biotechnology company dedicated to creating small molecule drugs in virology and immunology, today reported financial results for its fiscal first quarter ended december 31, 2023. “in 2024, enanta began a year which will be marked by execution and value creation across the company. we are preparing for multiple catalysts across our pipeline in 2024, starting with rsv, where we anticipate reporting to.
2024-02-06 07:00:00 - Press Release
Enanta Pharmaceuticals To Participate At The Oppenheimer 34th Annual Healthcare Life Sciences Conference
Watertown, mass.--(business wire)--enanta pharmaceuticals, inc. (nasdaq: enta), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that jay r. luly, ph.d., president and chief executive officer and tara l. kieffer, ph.d., chief product strategy officer, will participate in a fireside chat at the oppenheimer 34th annual healthcare life sciences conference on february 13, 2024 at 11:20 a.m. et. a live webca.
2024-01-31 07:00:00 - Press Release
Enanta Pharmaceuticals To Host Conference Call On February 7 At 4:30 P.m. Et To Discuss Its Financial Results For Its Fiscal First Quarter Ended December 31, 2023
Watertown, mass.--(business wire)--enanta pharmaceuticals, inc. (nasdaq: enta), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that it plans to report its financial results for its fiscal first quarter ended december 31, 2023 after the u.s. market closes on february 7, 2024. enanta management will host a conference call at 4:30 p.m. et to discuss these results and provide an update on the company's bu.
Latest News
2024-02-07 22:04:03 - Seeking Alpha
Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call Transcript
2024-02-07 18:11:09 - Zacks Investment Research
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue Estimates
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.18. This compares to loss of $1.39 per share a year ago.
2024-01-31 07:00:00 - Business Wire
Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2023
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2023 after the U.S. market closes on February 7, 2024. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on the company's bu.
2024-01-05 04:31:03 - Zacks Investment Research
Strength Seen in Enanta Pharmaceuticals (ENTA): Can Its 13.8% Jump Turn into More Strength?
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
2023-12-19 12:02:25 - Zacks Investment Research
5 Secret Santa Stocks to Pop Surprise Returns
Enanta Pharmaceuticals (ENTA), OneConnect Financial. (OCFT), KNOT Offshore (KNOP), Hippo Holdings (HIPO) and H World Group (HTHT) could surprise investors with big returns this Christmas.
2023-11-27 11:17:25 - Zacks Investment Research
How Much Upside is Left in Enanta Pharmaceuticals (ENTA)? Wall Street Analysts Think 88.23%
The mean of analysts' price targets for Enanta Pharmaceuticals (ENTA) points to an 88.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2023-11-20 21:43:05 - Seeking Alpha
Enanta Pharmaceuticals, Inc. (ENTA) Q4 2023 Earnings Call Transcript
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA ) Q4 2023 Earnings Conference Call November 20, 2023 4:30 PM ET Company Participants Jennifer Viera - Investor Relations Jay Luly - President and Chief Executive Officer Paul Mellett - Chief Financial Officer Scott Rottinghaus - Chief Medical Officer Conference Call Participants Roanna Ruiz - Leerink Partners Jay Olson - Oppenheimer Ed Arce - H.C. Wainwright & Company Eric Joseph - JPMorgan Liisa Bayko - Evercore Roy Buchanan - JMP Operator Good afternoon, and welcome to Enanta Pharmaceuticals Fiscal Fourth Quarter and Year-End Financial Results Conference Call.
2023-11-20 16:01:00 - Business Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today reported financial results for its fiscal fourth quarter and year ended September 30, 2023. “Throughout fiscal 2023, Enanta remained focused on advancing our two RSV clinical stage programs of best-in-class antivirals with different mechanisms of action. We are pleased to announ.
2023-11-13 07:00:00 - Business Wire
Enanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Full Year Ended September 30, 2023
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal fourth quarter and full year ended September 30, 2023 after the U.S. market closes on November 20, 2023. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on the company's busines.
2023-09-17 12:00:00 - Business Wire
Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-323, its oral, once-daily, L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at the 9th European Scientific Working Group on Influenza (ESWI) Influenza Conference on September 17-20, 2023 at the Palacio de Congresos.